List of Contents

Non-Invasive Cancer Diagnostics Market Size, Share, and Trends 2024 to 2034

The global non-invasive cancer diagnostics market size is calculated at USD 161.2 billion in 2024, grew to USD 173.13 billion in 2025 and is predicted to hit around USD 329.15 billion by 2034, expanding at a CAGR of 7.40% between 2024 and 2034.

  • Last Updated : October 2024
  • Report Code : 3391
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Cancer Diagnostics Market 

5.1. COVID-19 Landscape: Non-Invasive Cancer Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Cancer Diagnostics Market, By Type

8.1. Non-Invasive Cancer Diagnostics Market, by Type, 2024-2034

8.1.1. Lung  Cancer

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Breast Cancer

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Solid Tumors

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Blood Cancer

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Ovarian Cancer

8.1.5.1. Market Revenue and Forecast (2021-2034)

8.1.6. Colorectal Cancer

8.1.6.1. Market Revenue and Forecast (2021-2034)

8.1.7. Other

8.1.7.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Non-Invasive Cancer Diagnostics Market, By Product Type

9.1. Non-Invasive Cancer Diagnostics Market, by Product Type, 2024-2034

9.1.1. Immunochemistry

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Clinical Microbiology

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Point of Care Test (POCT)

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Hematology

9.1.4.1. Market Revenue and Forecast (2021-2034)

9.1.5. Hemostasis

9.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Non-Invasive Cancer Diagnostics Market, By Test Type 

10.1. Non-Invasive Cancer Diagnostics Market, by Test Type, 2024-2034

10.1.1. Urine Test

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Imaging Test

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Computerized Tomography

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Magnetic Resonance Imaging

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Nuclear Medicine Scans

10.1.5.1. Market Revenue and Forecast (2021-2034)

10.1.6. X-ray/Mammography

10.1.6.1. Market Revenue and Forecast (2021-2034)

10.1.7. Ultrasound

10.1.7.1. Market Revenue and Forecast (2021-2034)

10.1.8. Spectroscopy

10.1.8.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Non-Invasive Cancer Diagnostics Market, By Application

11.1. Non-Invasive Cancer Diagnostics Market, by Application, 2024-2034

11.1.1. Blood

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Urine

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Saliva

11.1.3.1. Market Revenue and Forecast (2021-2034)

cast (2021-2034)

Chapter 12. Global Non-Invasive Cancer Diagnostics Market, By End Users

12.1. Non-Invasive Cancer Diagnostics Market, by End Users, 2024-2034

12.1.1. Hospital and Clinics

12.1.1.1. Market Revenue and Forecast (2021-2034)

12.1.2. Diagnostic Centers

12.1.2.1. Market Revenue and Forecast (2021-2034)

12.1.3. Ambulatory care

12.1.3.1. Market Revenue and Forecast (2021-2034)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 13. Global Non-Invasive Cancer Diagnostics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type (2021-2034)

13.1.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.1.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.1.4. Market Revenue and Forecast, by Application (2021-2034)

13.1.5. Market Revenue and Forecast, by End Users (2021-2034)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type (2021-2034)

13.1.6.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.1.6.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.1.6.4. Market Revenue and Forecast, by Application (2021-2034)

13.1.6.5. Market Revenue and Forecast, by End Users (2021-2034) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Type (2021-2034)

13.1.7.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.1.7.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.1.7.4. Market Revenue and Forecast, by Application (2021-2034)

13.1.7.5. Market Revenue and Forecast, by End Users (2021-2034)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type (2021-2034)

13.2.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.2.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.2.4. Market Revenue and Forecast, by Application (2021-2034) 

13.2.5. Market Revenue and Forecast, by End Users (2021-2034) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type (2021-2034)

13.2.6.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.2.6.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.2.7. Market Revenue and Forecast, by Application (2021-2034) 

13.2.8. Market Revenue and Forecast, by End Users (2021-2034) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type (2021-2034)

13.2.9.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.2.9.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.2.10. Market Revenue and Forecast, by Application (2021-2034)

13.2.11. Market Revenue and Forecast, by End Users (2021-2034)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type (2021-2034)

13.2.12.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.2.12.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.2.12.4. Market Revenue and Forecast, by Application (2021-2034)

13.2.13. Market Revenue and Forecast, by End Users (2021-2034)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type (2021-2034)

13.2.14.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.2.14.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.2.14.4. Market Revenue and Forecast, by Application (2021-2034)

13.2.15. Market Revenue and Forecast, by End Users (2021-2034)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type (2021-2034)

13.3.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.3.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.3.4. Market Revenue and Forecast, by Application (2021-2034)

13.3.5. Market Revenue and Forecast, by End Users (2021-2034)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type (2021-2034)

13.3.6.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.3.6.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.3.6.4. Market Revenue and Forecast, by Application (2021-2034)

13.3.7. Market Revenue and Forecast, by End Users (2021-2034)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type (2021-2034)

13.3.8.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.3.8.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.3.8.4. Market Revenue and Forecast, by Application (2021-2034)

13.3.9. Market Revenue and Forecast, by End Users (2021-2034)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type (2021-2034)

13.3.10.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.3.10.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.3.10.4. Market Revenue and Forecast, by Application (2021-2034)

13.3.10.5. Market Revenue and Forecast, by End Users (2021-2034)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type (2021-2034)

13.3.11.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.3.11.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.3.11.4. Market Revenue and Forecast, by Application (2021-2034)

13.3.11.5. Market Revenue and Forecast, by End Users (2021-2034)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type (2021-2034)

13.4.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.4.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.4.4. Market Revenue and Forecast, by Application (2021-2034)

13.4.5. Market Revenue and Forecast, by End Users (2021-2034)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type (2021-2034)

13.4.6.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.4.6.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.4.6.4. Market Revenue and Forecast, by Application (2021-2034)

13.4.7. Market Revenue and Forecast, by End Users (2021-2034)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type (2021-2034)

13.4.8.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.4.8.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.4.8.4. Market Revenue and Forecast, by Application (2021-2034)

13.4.9. Market Revenue and Forecast, by End Users (2021-2034)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type (2021-2034)

13.4.10.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.4.10.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.4.10.4. Market Revenue and Forecast, by Application (2021-2034)

13.4.10.5. Market Revenue and Forecast, by End Users (2021-2034)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type (2021-2034)

13.4.11.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.4.11.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.4.11.4. Market Revenue and Forecast, by Application (2021-2034)

13.4.11.5. Market Revenue and Forecast, by End Users (2021-2034)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type (2021-2034)

13.5.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.5.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.5.4. Market Revenue and Forecast, by Application (2021-2034)

13.5.5. Market Revenue and Forecast, by End Users (2021-2034)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type (2021-2034)

13.5.6.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.5.6.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.5.6.4. Market Revenue and Forecast, by Application (2021-2034)

13.5.7. Market Revenue and Forecast, by End Users (2021-2034)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type (2021-2034)

13.5.8.2. Market Revenue and Forecast, by Product Type (2021-2034)

13.5.8.3. Market Revenue and Forecast, by Test Type (2021-2034)

13.5.8.4. Market Revenue and Forecast, by Application (2021-2034)

13.5.8.5. Market Revenue and Forecast, by End Users (2021-2034)

Chapter 14. Company Profiles

14.1. Abbott

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Thermo Fisher Scientific, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Illumina, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. QIAGEN

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. F. Hoffmann-La Roche Ltd

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Agilent Technologies, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Quest Diagnostics Incorporated.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Merck KGaA

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Hologic, Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. BD.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global non-invasive cancer diagnostics market size is expected to increase USD 329.15 billion by 2034 from USD 161.2 billion in 2024.

The global non-invasive cancer diagnostics market will register growth rate of 7.4% between 2024 and 2034.

The major players operating in the non-invasive cancer diagnostics market are Abbott, Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Quest Diagnostics Incorporated., Merck KGaA, Hologic, Inc., BD., GSK plc., Novartis AG, Bristol-Myers Squibb Company, Lilly., Pfizer, Inc., Myriad Genetics, Inc., and Others.

The driving factors of the non-invasive cancer diagnostics market are the relentless surge in global cancer cases is a potent catalyst propelling the expansion of the market.

North America region will lead the global non-invasive cancer diagnostics market during the forecast period 2024 to 2034.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us